
COURSE CREDITS & HOURS
14 AMA PRA Category 1 Credits™14 ANCC Contact Hours
11 Hours of Pharmacology for NPs
COURSE FEES
TARGET AUDIENCE
PROGRAM TOPICS
- Management of Hyperlipidemia: A cardiologists perspective
- Review the evidence to support the use of statins for primary and secondary prevention.
- Review the evidence to support the elimination of non-statin therapy from lipid treatment guidelines.
- Review of current national and international practice guidelines.
- Cardiac Risk Assessment: Risk calculators and incorporating cardiac imaging.
- Appreciate the value and limitations of cardiovascular risk calculators.
- Understand the utility and role of non-invasive arterial imaging modalities.
- Cardiac coronary artery CT imaging in the diagnosis of chest pain.
- Protocols for coronary artery CT imaging; benefits, risks and value?
- Identify appropriate candidates with chest pain syndromes for coronary artery CT imaging.
- The role of PCSK9 inhibitors in the treatment of atherosclerotic cardiovascular disease.
- Understand the role of PCSK9 inhibitor therapy in management of dyslipidemia.
- Review of clinical trials evaluating the clinical benefits of injectable PCSK9 treatment.
- Statin Intolerance/Resistance: Is the problem the patient or the drug?
- Understand the physiologic basis and incidence of statin intolerance.
- Review of treatment options for patients who are statin intolerant or resistant.
- Management of Symptomatic Stable CAD: Stents for everybody?
- Appreciate in which patients are percutaneous coronary intervention and surgical revascularization are useful.
- Review novel medical therapies for CAD.
- Plaque reversal: myth or reality?
- Is the development of atheroscleotic plaque an inevitable consequence of untreated cardiovascular risk factors?
- What is the evidence for interventions that claim to prevent plaque progression or promote plaque regression?
- New Diabetes Medications that Improve Cardiovascular Outcomes
- Review cardiovascular outcomes data for currently available diabetes medications including review of new classes of agents, GLP-1 agonists, SGT2 inhibitors, QR bromocriptine
- Lipoprotein (a), Homocysteine, Hypercoagulation and CV risk
- Review lp (a), homocystine, MTHFR as risk factors for cardiovascular disease.
- Discuss how to interpret and treat these biomarkers.
- Obesity from the Perspective of a Lipidologist: Root Cause Analysis
- *Identify medical factors, medications, insulin resistance as secondary causes of obesity and how to work up, address and treat these conditions
- *Discuss how diet, genomics, microbiome and environmental factors influence the treatment of obese patients.
- Heart Disease in Women: Putting Prevention into Practice
- Review cardiometabolic risk in women, use of advanced biomarkers and clinical application.
- Complex lipid management: case study review
- Develop practical approach to using advanced lipid testing as well as treatment approach to reduce residual risks in patients with high risk for events.
- Biomarkers: Role of Apo B, LDL-P vs LDL -C in primary and secondary prevention cardiovascular disease, also inflammation
- Review outcomes data for Apo B LDL P and cost effective approach to treatment using advanced testing. Learn concept of discordance of LDL C vs LDL P or ApoB























































